AN006030L
DPP4/CD26 Polyclonal antibody
Size
£120.60
Was £134.00
- SKU:
- AN006030L
- Additional Names:
- ADABP Protein,ADCP2 Protein,CD26 Protein,DPPIV Protein,Human,TP103 Protein,DPP,dipeptidylpeptidase,dipeptidyl-peptidase,dipeptidyl peptidase,T-cell activation antigen CD,adenosine deaminase complexing protein,DPP4,ADABP,ADCP2,CD26,DPPIV,TP103,Dipeptidyl peptidase IV,ADCP-2,dipeptidyl-peptidase 4,dipeptidyl peptidase 4,DPP IV,dipeptidylpeptidase 4,T-cell activation antigen CD26,adenosine deaminase complexing protein 2,dipeptidylpeptidase IV,Dipeptidyl peptidase IV (DPP IV)
- Application:
- WB
- Concentration:
- 1 mg/ml
- Purification:
- Affinity Purified
- Storage Conditions:
- -20[o]C Avoid freeze/thaw cycles.
- Supplier:
- Elabscience
- Host:
- Rabbit
- Reactivities:
- Mouse, Rat
- Buffer:
- PBS with 0.05% Proclin300, 1% protective protein and 50% glycerol, pH7.4
- Immunogen:
- Recombinant Human DPP4/CD26 protein expressed by Mammalian
- Uniprot:
- P27487
- Synonyms:
- ADABP;ADCP-2;ADCP2;adenosine deaminase complexing protein 2;CD26;dipeptidyl peptidase 4;dipeptidyl peptidase IV;dipeptidylpeptidase 4;dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2);DPP IV;DPPIV;Gly-Pro naphthylamidase;Post-proline dipeptidyl aminopeptidase IV;T-cell activation antigen CD26;TP103;Xaa-Pro-dipeptidylaminopeptidase
- Extra Details:
- Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.
- Shipping Conditions:
- Blue Ice